90
Views
4
CrossRef citations to date
0
Altmetric
Review

Novel anti-inflammatory treatments for asthma

&
Pages 617-629 | Published online: 09 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

James Edward Pease & Richard Horuk. (2014) Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4. Expert Opinion on Drug Discovery 9:5, pages 467-483.
Read now
Gwijde FJPM Adriaensen & Wytske J Fokkens. (2013) Chronic rhinosinusitis: an update on current pharmacotherapy. Expert Opinion on Pharmacotherapy 14:17, pages 2351-2360.
Read now

Articles from other publishers (2)

Marek Wiśniewski, Adam Bieniek, Katarzyna Roszek, Joanna Czarnecka, Paulina Bolibok, Pilar FerrerIvan da SilvaArtur P. Terzyk. (2018) Cystine-based MBioF for Maintaining the Antioxidant–Oxidant Balance in Airway Diseases. ACS Medicinal Chemistry Letters 9:12, pages 1280-1284.
Crossref
William W. Busse, Rohit Katial, David Gossage, Suha Sari, Bing Wang, Roland Kolbeck, Anthony J. Coyle, Masamichi Koike, George L. Spitalny, Peter A. Kiener, Gregory P. Geba & Nestor A. Molfino. (2010) Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti–IL-5 receptor α antibody, in a phase I study of subjects with mild asthma. Journal of Allergy and Clinical Immunology 125:6, pages 1237-1244.e2.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.